Stock Scorecard
Stock Summary for GSK Plc (GSK) - $48.27 as of 12/3/2025 4:01:14 PM EST
Total Score
11 out of 30
Safety Score
62 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for GSK
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for GSK
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for GSK
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for GSK
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for GSK (62 out of 100)
| Stock Price Rating (Max of 10) | 8 |
| Historical Stock Price Rating (Max of 10) | 8 |
| Stock Price Trend (Max of 10) | 7 |
| Book Value (Max of 10) | 3 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 2 |
| Analyst Strong Buy Ratings (Max of 5) | 3 |
| Dividend Yield Percentage (Max of 10) | 6 |
| Operating Margin (Max of 10) | 6 |
| Trading Volume (Max of 10) | 10 |
| Price to Earnings (Max of 10) | 9 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for GSK
Financial Details for GSK
Company Overview |
|
|---|---|
| Ticker | GSK |
| Company Name | GSK Plc |
| Country | USA |
| Description | GlaxoSmithKline PLC (GSK) is a leading global biopharmaceutical company based in Brentford, UK, focused on enhancing health outcomes through its pioneering pharmaceuticals, vaccines, and consumer healthcare offerings. With a strong emphasis on research and development, GSK addresses critical global health challenges and maintains a diversified portfolio across key therapeutic areas. The company’s strategic commitment to innovation and sustainability not only positions it as a prominent player in the healthcare sector but also presents compelling investment opportunities for institutional investors looking to engage with the dynamic biopharmaceutical industry. |
| Sector Name | HEALTHCARE |
| Industry Name | DRUG MANUFACTURERS - GENERAL |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | 2/4/2026 |
Stock Price History |
|
| Last Day Price | 48.27 |
| Price 4 Years Ago | 46.78 |
| Last Day Price Updated | 12/3/2025 4:01:14 PM EST |
| Last Day Volume | 3,694,580 |
| Average Daily Volume | 5,395,671 |
| 52-Week High | 49.31 |
| 52-Week Low | 30.41 |
| Last Price to 52 Week Low | 58.73% |
Valuation Measures |
|
| Trailing PE | 13.41 |
| Industry PE | 28.63 |
| Sector PE | 88.06 |
| 5-Year Average PE | 9.66 |
| Free Cash Flow Ratio | 21.94 |
| Industry Free Cash Flow Ratio | 29.64 |
| Sector Free Cash Flow Ratio | 28.78 |
| Current Ratio Most Recent Quarter | 0.84 |
| Total Cash Per Share | 2.20 |
| Book Value Per Share Most Recent Quarter | 4.01 |
| Price to Book Ratio | 4.46 |
| Industry Price to Book Ratio | 10.41 |
| Sector Price to Book Ratio | 33.12 |
| Price to Sales Ratio Twelve Trailing Months | 3.06 |
| Industry Price to Sales Ratio Twelve Trailing Months | 4.17 |
| Sector Price to Sales Ratio Twelve Trailing Months | 15.97 |
| Analyst Buy Ratings | 1 |
| Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
| Total Shares Outstanding | 2,018,811,000 |
| Market Capitalization | 97,448,006,970 |
| Institutional Ownership | 19.17% |
Dividends |
|
| Ex-Dividend Date | 11/14/2025 |
| Previous Dividend Amount | 0.4300 |
| Current Dividend Amount | 0.4171 |
| Total Years Dividend Increasing | 0 |
| Trailing Annual Dividend Rate | 1.69 |
| Trailing Annual Dividend Yield | 3.51% |
| Forward Annual Dividend Rate | 1.67 |
| Forward Annual Dividend Yield | 3.46% |
| 5-Year Dividend Payments Count | 20 |
| 3-Year Average Dividend Yield | 4.45% |
| 5-Year Average Dividend Yield | 5.22% |
| 1-Year Dividend Growth Rate Percentage | 8.37% |
| 3-Year Dividend Growth Rate Percentage | 9.74% |
| 5-Year Dividend Growth Rate Percentage | -11.44% |
| All-Time Dividend Growth Rate Percentage | 0.67% |
| Dividend Payout Ratio | 48.27% |
Income Statement |
|
| Quarterly Earnings Growth YOY | 23.20% |
| Annual Earnings Growth | -47.75% |
| Reported EPS 12 Trailing Months | 3.60 |
| Reported EPS Past Year | 3.90 |
| Reported EPS Prior Year | 4.06 |
| Net Income Twelve Trailing Months | 5,494,000,000 |
| Net Income Past Year | 2,575,000,000 |
| Net Income Prior Year | 4,928,000,000 |
| Quarterly Revenue Growth YOY | 6.70% |
| 5-Year Revenue Growth | -1.45% |
| Operating Margin Twelve Trailing Months | 32.60% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 4,437,240,000 |
| Total Cash Past Year | 3,693,000,000 |
| Total Cash Prior Year | 3,742,812,800 |
| Net Cash Position Most Recent Quarter | -10,866,760,000 |
| Net Cash Position Past Year | -10,010,000,000 |
| Long Term Debt Past Year | 13,703,000,000 |
| Long Term Debt Prior Year | 14,154,000,000 |
| Total Debt Most Recent Quarter | 15,304,000,000 |
| Equity to Debt Ratio Past Year | 0.50 |
| Equity to Debt Ratio Most Recent Quarter | 0.59 |
| Total Stockholder Equity Past Year | 13,671,000,000 |
| Total Stockholder Equity Prior Year | 17,014,755,600 |
| Total Stockholder Equity Most Recent Quarter | 21,739,245,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 5,953,208,130 |
| Free Cash Flow Per Share Twelve Trailing Months | 2.95 |
| Free Cash Flow Past Year | 3,572,000,000 |
| Free Cash Flow Prior Year | 6,257,522,970 |
Options |
|
| Put/Call Ratio | 0.53 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.92 |
| MACD Signal | 0.97 |
| 20-Day Bollinger Lower Band | 34.92 |
| 20-Day Bollinger Middle Band | 42.22 |
| 20-Day Bollinger Upper Band | 49.52 |
| Beta | 0.23 |
| RSI | 68.27 |
| 50-Day SMA | 38.28 |
| 150-Day SMA | 36.13 |
| 200-Day SMA | 36.60 |
System |
|
| Modified | 12/4/2025 12:37:47 AM EST |